ArticleJournal of the National Cancer Institute2025
Disparities in the availability of and access to neuro-oncology trial-supporting infrastructure in the United States.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Patient navigation in neuro-oncology: A scoping review of programs supporting patients with CNS tumors.Equity neuroscience · 2026Article
- Natural history study of adults with primary central nervous system tumors: Initial results for first 1000 participants.Neuro-oncology practice · 2026Article
- Socioeconomic disparities in patient-reported outcomes, health literacy, and access to care among patients with primary brain tumors: findings from the All of Us Research Program.Journal of neuro-oncology · 2025Article
- Gaps in Diagnosis, Treatment, and Outcomes Among Patients with Brain Tumors in the United States: A State-of-the-Art Review.Cancers · 2025Review
- Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997-2025).Human vaccines & immunotherapeutics · 2025Article
- Imaging in Neuro-oncology.Seminars in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We conducted an extensive assessment and quantification of the reach of the oncology clinical trial-supporting infrastructure in the United States. Although our primary focus was on identifying avenues to expand the reach of neuro-oncology clinical trials, we considered infrastructure layers with important implications for broader cancer research and care. Specifically, we examined the geographic, population, and socioeconomic reach of national collaboratives (including more than 1500 institutions); more than 600 academic oncology and neurosurgery training programs; and networks of more than 25 000 individual neuro-oncology, neurosurgery, and general oncology (including hematology, medical, and gynecological oncology; surgical oncology; and radiation oncology) clinicians. Our study found that more than 57% of the US population lacks direct access to trial-supporting infrastructure. More than 71% of the locations with infrastructure are urban, and more than 72% are in socioeconomically advantaged areas. Our findings reveal critical disparities in oncology care access, and we suggest actionable strategies to optimize and expand the existing infrastructure's reach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.